Monitoring Use of Current and Emerging Therapies for Beta Thalassemia: Treatment and Management Pearls for Pharmacists

Monitoring Use of Current and Emerging Therapies for Beta Thalassemia: Treatment and Management Pearls for Pharmacists is organized by Pharmacy Times Continuing Education (PTCE).,Release date: June 15, 2022,Expiration date: June 15, 2023,Description:,Advances in treatments for beta-thalassemia have extended the lifespan of patients. Treatment and management strategies depend on the severity of the disease, though standard-of-care therapies generally include regular blood transfusions and iron chelation therapy. Pharmacists are crucial members of the multidisciplinary care team and can assist in improving access to therapy and transitions of care for patients to improve their quality of life. This activity will equip pharmacists with counseling pearls to educate patients and caregivers about beta thalassemia treatment options, risk factors, and adverse effects of therapy.,Educational Objectives,At the completion of this activity, pharmacists will be able to:,• Examine the etiology and pathophysiology of beta thalassemia, including the difference between transfusion-dependent and non-transfusion-dependent disease,• Compare the emerging treatments including their mechanisms of action and clinical trial data as well as factors affecting the utilization of therapies in the care of patients with beta-thalassemia,• Provide personalized education for patients about their disease and the treatments they are receiving